Brain

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER...

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025

Basel, 24 July 2025 Group sales grew by 7%1 at constant exchange rates (CER; 4% in CHF), driven by strong...

Tiny Blue Dot Foundation Awards $9M for Perception Box Neuroscience Exploring Youth Mental Health, Psychedelics, VR Therapy, Body Image, and Emotional Resilience

Spanning 11 studies across the U.S., Canada, Sweden, and Australia, the newly funded research explores interventions for young people dealing...

Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences,...

Linus Health Showcases Digital Breakthroughs to Advance Early Detection and Personalization in Brain Health at AAIC 2025

Powering Alzheimer's research with AI-driven insights across cognition, meaning, motor function, and speech — accelerating study recruitment and enabling more...

Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with IXICO for the Transformative Bio-Hermes-002 Study

IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementiasWASHINGTON, July 22, 2025 (GLOBE...

error: Content is protected !!